Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2011 by Benaya Rozen-Zvi, Meir Medical Center.
Recruitment status was: Not yet recruiting
Information provided by (Responsible Party):
Benaya Rozen-Zvi, Meir Medical Center
First received: August 23, 2011
Last updated: August 24, 2011
Last verified: August 2011
The study hypothesis is that urine concentrating ability can predict the rate of kidney function decline.
Patients with kidney disease at the investigatorsclinic will be asked to give first morning urine sample and osmolarity will be measured. The investigators will follow up kidney function decline and check if there is association with urine osmolarity.
||Observational Model: Cohort
Time Perspective: Prospective
||Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||October 2013 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Patients with CKD and estimated GFR of less then 50 mL per minute.
- Patients with CKD and estimated GFR of less then 50 mL per minute estimated by the short MDRD equation base on two creatinine values taken at least two weeks apart and are not getting steroids or immunosuppressive medication as treatment for their primary kidney disease.
- Life expectancy of less then 6 month.
- Expected to start renal replacement therapy within 3 month.
- Acute or acute on chronic renal failure with reversible component.
- Treatment with AVP inhibitors.
- Chronic hyponatremia (Na+<135 in two measurement two weeks apart).
- Primary polydipsia.
- Inability to give informed consent.
- Clinical hypovolemia.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01423045
|Pre dialysis clinic Dan Petach Tiqua county General health service
|Ganey Tiqua, Israel, 55900 |
|Contact: Benaya Rozen-zvi, MD 050-8773766 email@example.com |
|Contact: Boris Zingerman, MD 050-6260428 firstname.lastname@example.org |
||Benaya Rozen-Zvi, MD
||General health services - Dan Petach tiqua county
||Benaya Rozen-Zvi, attending nephrologist pre dialysis clinic Dan petach-tiqua county, Meir Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 23, 2011
||August 24, 2011
Keywords provided by Benaya Rozen-Zvi, Meir Medical Center:
Chronic kidney disease
Glomerular filtration rate
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 19, 2017
Renal Insufficiency, Chronic